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Abstract
Clorapine is an atypical antipsychotic agent associated with a higherfrequency ofseizures
than standard neuroleptics. In addition, clozapinecauses epileptiform abnormalities in the EEG in
up to 72% qf patients. A patient who developed a generalized seizure shortly after beginning
clozapine treatment and the patient's EEG fi ndings are presented. The neuropharmacology qf
dozapine and the management ofcioeapine-induced seizures and EEG abnormalities are discussed.
C lozapine (C lozaril) is a unique ant ipsychotic whi ch has been shown to be
effec t ive in th e treatment of refract ory schizo phe nia ( 1,2). Com pa red with standard
neuroleptics clozapine has minimal ext ra pyra midal side effects a nd poses a low risk
for tardive dysk inesia (1,3,4,5,6).
Develop ed in 1960, clozapine was delayed from earl ie r wid esp read use by it s side
effec t profile. The most dangerous of th e com mo n side effects is agranu locytosis ,
which has been re po rted in I% to 2% of cas es (7). Other adverse effects include
hypotension, fatigu e, drug fever, pharmacogenic delirium, tachycardia, a nd seizu res .
Associat ed se izu re s have be en found in 4% of U.S . cases (7) com pa red to I% to 2% in
standard neurolept ics (8) . Data from th e manufacturer, Sandoz, indicat es tha t these
seizures are dos e dependent with patients treated with 600 to 900 mg/day having a
se izu re fr equency of 5%; those treated with 300 to 599 mg/day, 3-4%; a nd those
patients treated with less than 300 mg/day having a se izu re frequency of 1- 2% (9). A
sim ilar dos e depen den t frequ ency was found by Devinsky et aI, who also sugges t that
rapid upward titrat ion of cloz apine may incr ease se izu re risk ( 10) .
EEG abnorma liti es have been not ed in 72% of patient s on clozapine (II) . T he
EEG typicall y shows slow waves a nd paroxysmal d isch a rg es whi ch may ap pear to be
epilep tifor m. As clozapine use incr eases, th e issue of how to man age clozapine-
induced seizures and EEG changes becomes a n important clinica l pro blem .
In this report we present th e case of a pat ient who had a se izu re while on a low
do se of clozapine and an abnormal EEG wh ich persisted for weeks a fter her last
seizure. This is follow ed by a discu ssion of th e unique pr op erties of clozapine which
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may con t ribu te to it s incr eased seizure fr equen cy, it s effect on EEG's, and a review of
curre n t guide lines in th e clinical man agement of clozapine-induced seizures .
CASE REPORT
Ms. B. is a 64 year old whit e femal e, gro up home residen t , with no medi cal
pr obl ems who has a 40 year hist ory of chro nic undi fferent iat ed sch izophreni a. Her
psych osis and disorganized beh avior had been re fractory to electroconvu lsive th erapy
a nd trials of multiple neuroleptics. The patient was most recently on haloperidol and
lithium when she develop ed a seve re dyst oni c reacti on. These medicat ions were
di scontinued and treatment with cloza pine was initiated as a n outpa tient. An initial
dose of 25 mg/day was incr eased 25 mg eve ry two days. O n day 14 of clozapine
treatment, a t a dos e of 175 mg/day, the patient had a witnessed gen eralized
tonic-clonic se izu re. At this time she fell to th e floor , had clo nic move ments of all
ex t re mit ies lasting approximately two minutes th en became flaccid an d unresponsive
for a nothe r two minutes. Upon regaining consc ious ness she ex pe rie nced a one hour
period of confusion and di sorientation . The patient had no histo ry of seizures , head
trauma , or subst a nce abuse . She had no kn own me dical condi tio ns or recent
med ication cha nges other th en sta r t ing cloza pine which put her a t increased risk for
a se izure. TO additional ge neralized se izures were noted. The group hom e treatment
tea m did not seek immedi at e medi cal cons ultatio n a nd cont in ued cloz apine treat -
ment a t a dose of 175 mg/day. Her beh avior remained d isorganized for seven days
afte r th e se izu re and she was admi tted to the psychi atric hospital for evalua t ion of
he r prolon ged change in ment al status.
Ne uro log ic ex a m reveal ed psych omotor re tarda t ion and confusion without focal
se nso ry or mot or findings a nd th e remai nd er of the ph ysical exam was unremarkabl e.
Met abolic, toxicology, endoc rine, infecti ou s a nd hema tological scree ns as well as a
head CT we re unremarkabl e. Ini tial EEG obtaine d nine days after th e witnessed
se izu re, with th e patient st ill on clozapine, showed bet a rhythms in the ba ckground
secondary to treatment with benzodiazepines a nd bri ef runs of diffuse high voltage
slow a nd sharp wave paroxysm al di sch arges as shown in Figure I.
Du e to conce rn abou t her prolon ged ence pha lopa thy clozapine was discontinued
and th e patient was sta r te d on ca rba mazepine. The a u thors were called in for
neurological consulta tion a t this tim e. Follow-up EEG 15 days a fter sto pping th e
clozapine showed resolution of epile pt ifor m activity.
DISCUSSION
Dopamine Receptors and ClozapineAction
A great deal of information abo u t dop amine receptor subtypes has recent ly
become ava ilable whi ch sho uld she d light on clozapine 's a n tipsychotic and proconvul-
sa n t effec ts. Dop amine rece p to rs are glycopro te in molecul es, locat ed on pr e-synaptic
a nd post-synaptic membra nes a nd found primarily in th e st r ia tum , cortex and limbic
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FIGURE 1. reveals beta rhythms in the background and f r equen t pa roxysmal bursts of
slow and s h a r p wave discharges.
syste m . Until recently, dopamine receptors have been ca tegorize d int o D 1 and D2
subtypes. D 1 receptors are the most abundan t dopaminergic rece ptors in the human
brain. They are found in both striatal and cor t ico-lim bic a reas, and they activat e
ade nyla te cyclase and cyclic AMP. D2 recep to rs are found in greates t concen trat ion in
th e st r ia tum and were t ho ug h t to inhibit cyclic AMP. Ne uro lep tic potency has been
rated by th e dose required to antagonize th e D2 receptor. Advances in molecular
CLOZAPINE-INDUCED SEIZURES AND EEG CHANGES 39
biology have led to the cloning of genes for 2 typ es of D, a nd D2receptors ( 12,13) and
th e dis covery of D3 , D4 and D, re ceptors (14 ,15) . The D3_S receptor s a ppear to be
localized primarily outside th e striatum in cor t ica l and limbic region s.
The me chanism of clozapine's clinical antipsychotic efficacy has prompted a
great deal of investigation. The neuropharmacology of clozapine was rec ently re-
viewed by Baldessarini and Frankenberg (16) and Meltzer (17). C loza pine is a weak
antagonist a t th e dopamine D 1 and D2 rec eptors and moderat e an tagonist of 5HT2,
5H T3, alpha I, alpha 2 and bet a-adren ergic receptors and exhibits a n tic ho linergic
and antihistiminic properties . Recent work ha s pointed to D4 and D3 a n tagonism as
th e possible medi ator of th e antipsychotic ac t ivity of clozapine (14,15). Ne urophysio-
logi c studies of clozapine indicate a pr eferential effec t on th e A I0 neu ron s pr oj ect ing
to limbic areas and minimal affect on th e A9 neurons pr ojecting in to th e bas al
ganglia (18). The D4 receptor appears to be loca ted primarily outside the striatum
which could explain clozapine 's lack of significant ex t ra pyramida l effec ts .
Dopamine and Seiz ures
H ow dopamine antagonists induce seizures is not well underst ood . Som e eVI-
dence points to dopamine as a regulator of se izu re acti vit y (19). The specifi c ro le
whi ch each dopamine receptor plays has ye t to be fully resolved. Loscher and
C zuczwar and Turski e t al found that D2 agonist s su ch as L-D op a and th e mixed D b
D2 agonist apomorphine had an anticonvulsant effec t whil e D2 an tagonists, like
clozapine, tend to lower th e seizure threshold (19 ,20 ,21 ,22). These da ta suggest that
clozapine's blockade of D2 receptors is responsibl e for its associa te d se izu res but th is
do es not explain th e incr eased preval en ce of clozapine relat ed se izures compared to
st andard neuroleptics. Burke e t al demonstrated th e opposite effec t with D, receptor
com pounds (19) . In his study in mi ce, D, agonist s lower th e se izu re threshold to
pilocarpine and picrotoxin and D 1 antagonists ex erted a protecti ve effect against
seizures. An additional mechanism is suggest ed by Giardino et al who repor ted a
de cr ease in benzodiazepine re ceptor density in rat cor te x a fte r chro nic clozapine
administration (23), raising th e possibility that clozapine could alt er t he seizure
threshold throughits effec ts on GABA- ergic syst ems.
EEG Changes Du ring Cloeapine Treatment
The patient described in this report had epil eptiform disch arges on her EEG
following administration of clozapine. Re cent studies su ggest th at most patients
receiving clozapine have abnormal EEGs (11 ,24,2 5) . These changes have be en
reported to be dos e related (26) but cha nges have been noted a fte r a sin gle dose (27) .
Tiihonen et al found that 16 of 16 subjects studied had profound disturban ces of
background activity and also paroxysms consist ing of delt a a nd th et a waves, seven
patients had paroxysms which were classified as epilept iform, cons ist ing of sp ikes,
polyspikes , or spikes and slow wave com plexe s (24) . These findin gs corre la te with an
ea rlie r study by Isermann and Haupt who found 26 of 36 subjects st udi ed had
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abnormal EEGs after beginning clozapine (II) . Fifteen had paroxysm al episodes of
generalized slowing and 8 had epilep t iform dis charges . Koukkou also suggest ed tha t
clozapine-induced EEG cha nges a re associat ed with a better respon se to clozapine
than those patients whose EEGs remain normal (25).
Management ofClozapine-Induced S eizures
We present this case since th e management of this patient bro ught ou t a
number of important points concerning clozapine-induced seizu res . The g roup home
treatment team was unfamiliar with th e management of cloz apine-indu ced seizu res
as evide nced by th e continuation of the clozapine a t th e sam e do se a fte r the seizure
and the seven day delay in obtaining a medical eva lua tion.
Several recent papers comment on the management of cloza pine-r elat ed se i-
zures (7, 10,16 ,28,29,30) . Prevention of seizures ca n be enha nced by: I) no t exceeding
dos es of 600 mg/day; 2) slowly increasing daily dos es; and 3) avoidi ng concomitan t
use of other medications whi ch also lower th e seizure threshold . For exa m ple,
lithium, neuroleptics and tricyclic antidepressants ca n lower th e seizure th reshold .
It is not known if pre-existing subclinical EEG abnor malit ies incr ease a patien t 's
risk for seizures while on clozapine but at pr esent , we do not recommend a n EEG for
all patients prior to beginning cloz apine treatm ent. Patients with a hist ory of seizu res
and /or confusional sta tes should have a ba seline EEG before star t ing clozapine. An
EEG should also be performed on patients who have a cha nge in ment al status or
seizure while on cloz apine. In th e case described this ste p should have been taken
imm ediately after th e patient had the seizure.
Subclinical EEG changes in the abse nce of associated clin ical findi ngs do not
necessarily require a n alteration in clozapine treatment. Cl ozapine-relat ed se izures
are not a n absolute indication for discontinuation of th erapy bu t cer tain ste ps, which
were not follow ed in th e cas e described , should be taken immediat ely a fter suc h an
eve nt. Other possible causes of seizure should be investigated . This work-up sho uld
include EEG, head CT, laboratory evalua tion and possibl y a neurological consulta-
tion. Following a seizure, clozapine should be held until th e patient 's mental sta te
returns to baseline and th en th e daily dos e of cloz apine should be reduced . Lieber-
man et al suggest a 50% reduction in th e daily dos e (7). The manufactu rer sta te s t ha t
31 of th e 41 cases in whi ch seizures developed remained on cloz apine despit e se izures .
Less than 5% have had a second seizure with simultaneou s treatm ent with valpro ic
acid (data on file, Sandoz Pharmaceuticals, 1991) . In th e case pr esented clozapine
had not yet demonstrated an antipsychotic effec t and th e t reatment team decided to
dis continue her cloz apine and use ca rba maze pine tempor arily to stabilize her mental
state .
A lack of consensus exists conce r ning th e concomita n t use of an t iconvu lsa nts
after a clozapine-induced seizure. If a clinician decid es to use a n a nt iconvulsan t ,
valproic acid is th e drug of choice as ph en ytoin may ca use a decr ease in clozapine
plasma levels (31) and ca rba mazepine should be avoide d du e to th e possib ility of
depress ed granulocyte production. One death has been rep ort ed in a pa tien t on
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combine d treatment of clozapine a nd carba maze pine (data on file, Sa nd oz Ph ar ma-
ce utica ls, 1991) .
Kane suggests th at th ere may be as many as 100,000 to 200,000 schizophrenics
resist ant to sta ndard neuroleptics in th e U.S. ( I) . C urren t ly there a re a pproximately
23,000 individuals in th e U.S. being t rea ted with clozapine. The use of clozapine will
cer tainly incr ease in th e 1990 's. We believe thi s pap er addresses th e import ant need
for clinicians to cont inue to further th eir underst a nding of clozap ine a nd th e
management of its side effects such as seizu res a nd EEG cha nges.
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